Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: An observational study

Advances in Therapy

Volumn 31, Issue 7, 2014, Pages 762-775

  Hu, Dayi ^a   Liu, Lisheng ^b   Li, Weimin ^c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Amlodipine; Blood pressure; Cardiology; Hypertension; Single pill combination; Valsartan

Indexed keywords

AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CHEMICALLY INDUCED; CHINA; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE, VALSARTAN DRUG COMBINATION; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CHINA; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EDEMA; FEMALE; HEADACHE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84905924331     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0132-x     Document Type: Article

References (38)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23. (Pubitemid 40138015)
2. Krzesinski JM, Cohen EP. Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. Core Evid. 2010;4:1-11.
3. He J, Gu D, Chen J, et al. Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet. 2009;374:1765-72.
4. Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation. 2008;118:2679-86.
5. Li YC, Wang LM, Jiang Y, et al. Prevalence of hypertension among Chinese adults in 2010. Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46:409-13.
6. Liu LS. Writing group of Chinese guidelines for the management of H (2010 Chinese guidelines for the management of hypertension). Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579-615.
7. Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension. 2002;40:920-7. (Pubitemid 35434917)
8. Bangalore S, Shahane A, Parkar S, et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007;9:184-9. (Pubitemid 46894812)
9. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-62. (Pubitemid 34208333)
10. Karpov Y, Dongre N, Vigdorchik A, et al. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the reallife safety and effectiveness in the routine treatment of hypertension. Adv Ther. 2012;29:134-47.
11. Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther. 2008;25:399-411.
12. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens. 2008;2:294-302.
13. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23:479-89.
14. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-80. (Pubitemid 47028551)
15. Hypertension EETFftMoA. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31:1925-38.
16. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-45. (Pubitemid 47400613)
17. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31. (Pubitemid 38781102)
18. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the angloscandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. (Pubitemid 41265663)
19. Schunkert H, Glazer RD, Wernsing M, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. Curr Med Res Opin. 2009;25:2655-62.
20. Ke YN, Huang J, Zhu JR, et al. Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37:794-9.
21. Zhu D, Yang K, Sun N, et al. Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives. Int J Cardiol. 2013;167:2024-30.
22. Ke Y, Zhu D, Hong H, et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin. 2010;26:1705-13.
23. Huang J, Sun NL, Hao YM, et al. Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. Clin Exp Hypertens. 2011;33:179-86.
24. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9:355-64.
25. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2007;25:1105-87. (Pubitemid 46924065)
26. Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther. 2008;25:300-20.
27. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32-9.
28. Fogari R, Zoppi A, Mugellini A, et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr. 2009;48:401-5.
29. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-89. (Pubitemid 46661857)
30. Hu DY, Liu LS, Yu JM, et al. National survey of blood pressure control rate in Chinese hypertensive outpatients-China STATUS. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38:230-8.
31. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the exforge in failure after single therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10:185-94.
32. Trenkwalder P, Schaetzl R, Borbas E, et al. Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. Blood Press Suppl. 2008;2:13-21.
33. RL. Exforge: a new combination to treat hypertension. Pharma Note. 2008; 23:1-11.
34. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-9. (Pubitemid 47176510)
35. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension. 2010;55:399-407.
36. Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate - a meta-analysis of randomized trials. J Hypertens. 2011;29:1270-80.
37. Elliott WJ. Management of hypertension in the very elderly patient. Hypertension. 2004;44:800-4. (Pubitemid 39577400)
38. Wu ZB, Zhang Y, Yu QG, et al. Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40:8-13.